Dosing and switching strategies for quetiapine fumarate

Clinical Therapeutics

Volumn 24, Issue 2, 2002, Pages 209-222

  Cutler, Andrew J ^a,b   Goldstein, Jeffrey M ^c   Tumas, John A ^c  

^a Coordinated Research of Florida Inc ^*  (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c ASTRAZENECA   (United Kingdom)

Author keywords

Atypical antipsychotic agent; Dosing; Quetiapine; Schizophrenia; Switching

Indexed keywords

BENZODIAZEPINE; CLOZAPINE; HALOPERIDOL; KETOCONAZOLE; NEUROLEPTIC AGENT; OLANZAPINE; PHENYTOIN; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

CLINICAL TRIAL; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG METABOLISM; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; PSYCHOSIS; REMISSION; REVIEW; SCHIZOPHRENIA;

EID: 0036190196     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(02)85018-4     Document Type: Article

References (55)

1. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States
2. Review and management of clozapine side effects
3. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia
4. Atypical antipsychotics. Part I: Pharmacology, pharmacokinetics, and efficacy
5. A comparison of the effects of quetiapine ("Seroquel") and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment
6. Risperidone: A review of its use in the management of the behavioural and psychological symptoms of dementia
7. ICI 204,636 (Seroquel): A dibenzothiazepine atypical antipsychotic. Review of preclinical pharmacology and highlights of Phase II clinical trials
8. Seroquel and cognitive improvement in patients with schizophrenia
9. Attentional improvement following quetiapine fumarate treatment in schizophrenia
10. Rapid release of antipsychotic drugs from dopamine D2 receptors: An explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine
11. ICI 204,636, an atypical antipsychotic: Efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia
12. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo
13. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia
14. Quetiapine in patients with schizophrenia. A high-and low-dose double-blind comparison with placebo
15. The long-term efficacy and safety of "Seroquel" (quetiapine)
16. A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders - The QUEST study
17. Quetiapine, a novel antipsychotic: Experience in elderly patients with psychotic disorders
18. Long-term use of quetiapine in elderly patients with psychotic disorders
19. Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: An open-label trial in adolescents with psychotic disorders
20. Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease
21. Clozapine replacement by quetiapine for the treatment of drug-induced psychosis in Parkinson's disease
22. Efficacy of quetiapine in Parkinson's patients with psychosis
23. The long-term effect of quetiapine ("Seroquel") monotherapy on weight in patients with schizophrenia
24. Tolerability of atypical antipsychotics
25. Atypical antipsychotic agents: A critical review
26. Plasma prolactin in schizophrenia subjects treated with Seroquel (ICI 204,636)
27. Multiple-dose pharmacokinetics of "Seroquel" (quetiapine) in schizophrenic men and women
28. 2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia
29. A comparison of bd and tid dose regimens of quetiapine (Seroquel) in the treatment of schizophrenia
30. Improvement in cognitive functioning with long-term quetiapine is superior to haloperidol
31. Clinical pharmacokinetics of quetiapine: An atypical antipsychotic
32. The effect of phenytoin and cimetidine on the pharmacokinetics of Seroquel (quetiapine)
33. Pharmacokinetics and safety of lithium coadministered with Seroquel (quetiapine)
34. The effects of concomitant phenytoin administration on the steady-state pharmacokinetics of quetiapine
35. The safety and pharmacokinetics of quetiapine when coadministered with haloperidol, risperidone, or thioridazine
36. Multiple-dose pharmacokinetics of "Seroquel" (quetiapine) in elderly psychotic patients
37. Singledose pharmacokinetics of quetiapine in subjects with renal or hepatic impairment
38. New treatments for bipolar disorder: The role of atypical neuroleptic agents
39. Antipsychotics in the treatment of mood disorders and risk of tardive dyskinesia
40. Quetiapine alone and added to a mood stabilizer for serious mood disorders
41. Lamotrigine for the treatment of bipolar disorder: A clinical case series
42. Risperidone in the treatment of mania
43. Efficacy of olanzapine in acute bipolar mania: A double-blind, placebo-controlled study
44. Olanzapine therapy in treatment-resistant psychotic mood disorders: A long-term follow-up study
45. A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania
46. Risperidone safety and efficacy in the treatment of bipolar and schizoaffective disorders: Results from a 6-month, multicenter, open study
47. Switching antipsychotic medications
48. Cholinergic rebound and rapid onset psychosis following abrupt clozapine withdrawal
49. Relapse following clozapine withdrawal: Effect of neuroleptic drugs and cyproheptadine
50. Clinical implications of clozapine discontinuation: Report of an NIMH workshop
51. Clozapine withdrawal resulting in delirium with psychosis: A report of three cases
52. Immediate recurrence of psychotic symptoms after discontinuation of clozapine: A case report
53. Safety and tolerability of switching from conventional antipsychotic therapy to Seroquel® (quetiapine fumarate) followed by withdrawal from Seroquel